Multicenter Phase II Study of Gefitinib Mono-therapy or Gefitinib Combined With Pemetrexed/Cisplatin in Patients With Brain Metastases From Non-small Cell Lung Cancer Harboring EGFR Mutation
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Pemetrexed
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Oct 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
- 25 Oct 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2018.
- 29 Mar 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2017 as reported by ClinicalTrials.gov record.